scholarly journals Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Sasja F Mulder ◽  
Dirk Bertens ◽  
Ingrid ME Desar ◽  
Kris CP Vissers ◽  
Peter FA Mulders ◽  
...  
Keyword(s):  
Cognitive Functioning ◽  
Cancer Patients ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Sorafenib Treatment

scholarly journals Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: an institution-based comparative cross-sectional study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Edgeit Abebe ◽  
Tesfaye Tollesa ◽  
Mathewos Assefa ◽  
Zelalem Tilahun ◽  
Yohannes Dinku ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Functioning ◽  
Cancer Patients ◽  
Addis Ababa ◽  
Cross Sectional Study ◽  
Breast Cancer Patients ◽  
Sectional Study ◽  
Cross Sectional ◽  
Specialized Hospital ◽  
Tikur Anbessa Specialized Hospital

Abstract Background Breast cancer is the second leading cause of cancer in the world. It is the commonest type of cancer in Ethiopia. Cognitive problems are common among breast cancer patients. The study aimed to assess cognitive functioning and its associated factors among breast cancer patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia 2020. Methods Institution-based comparative cross-sectional study was conducted. Study subjects were 117 breast cancer patients on chemotherapy and 117 women without breast cancer who volunteered for the study. Data was collected from May–June 2020. The Mini-mental status exam (MMSE) was used to assess cognitive functioning. Data were entered into Epi Data version 4.6.0.2 and analyzed using STATA version 14 software. Univariable and multivariable linear regression model was fitted to identify factors associated with cognitive functioning. A two-tailed p-value less than 0.05 was used to declare statistical significance. Results Among the total breast cancer patients 41.9% were diagnosed with earlier sage of the diseases (stage I and II), while the rest 58.1% were diagnosed with stage III and stage IV breast cancer. A significant difference in the MMSE score was observed among breast cancer patients and controls (19.76 ± 5.29, 25.18 ± 4.68 p <  0.0001) respectively. In multivariable linear regression analysis being non-breast cancer (Adjusted beta coefficient (Adj.β.coff). = 3.34, 95% CI (1.92–4.76) p <  0.001), hemoglobin gm/dl (Adj.β.coff =0.34, 95% CI (0.04–0.63) p = 0.02), and primary education (Adj.β.coff =2.98 95%CI (1.16–4.96) p = 0.001) secondary level and more education (Adj.β.coff = 5.47, 95%CI (3.51–7.28) p < 0.001) were significantly associated with MMSE cognitive score. Conclusion Breast cancer patients had lower mean MMSE scores when compared to non-breast cancer women. Higher hemoglobin level and higher level of education increase the MMSE cognitive score. Clinicians should incorporate routine screening of cognitive functioning for breast cancer patients and further study is required to evaluate cognitive impairment among breast cancer patients in Ethiopia.

scholarly journals Cognitive Functioning and its Associated Factors among Breast Cancer Patients on Chemotherapy at Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia: An Institution-Based Comparative Cross-Sectional Study

2021 ◽  
Author(s):  
Edgeit Abebe ◽  
Tesfaye Tollesa ◽  
Mathewos Assefa ◽  
Zelalem Tilahun ◽  
Yohannes Dinku ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cognitive Functioning ◽  
Cancer Patients ◽  
Associated Factors ◽  
Cross Sectional Study ◽  
Breast Cancer Patients ◽  
Sectional Study ◽  
Cross Sectional ◽  
Specialized Hospital ◽  
Tikur Anbessa Specialized Hospital

Abstract Background: Breast cancer is the second leading cause of cancer in the world. It is the commonest type of cancer in Ethiopia. Cognitive problems are common among breast cancer patients especially if they are treated with chemotherapy. The study aimed to assess cognitive functioning and its associated factors among breast cancer patients at Tikur Anbessa Specialized Hospital, Ethiopia 2020.Methods: Institution-based comparative cross-sectional study was conducted. Study subjects were 117 breast cancer patients on chemotherapy and 117 women without breast cancer who volunteered for the study. Data was collected from May - June 2020. The Mini-mental status exam was used to assess cognitive functioning. Data was entered into Epi Data version 4.6.0.2 and analyzed using STATA software version 14. Univariable and multivariable linear regression model was fitted to identify factors associated with cognitive functioning. A two-tailed p-value lower than 0.05 was used to declare statistical significance.Results: Significant difference in the MMSE score was observed among breast cancer patients and controls (19.76 ±5.29, 25.18±4.68 p< 0.0001) respectively. In multivariable linear regression analysis being non-breast cancer (controls) (std.β 3.34, 95% CI [1.92 4.76] p<0.001), hemoglobin gm/dl (std. β 0.34, 95 % CI [0.04 0.63] p=0.02), and primary education (Adj. β 2.98 95 %CI [1.16 4.96] p=0.001) secondary level and more education (std. β 5.47, 95 %CI [3.51 7.28] p<0.001) were significantly associated with MMSE cognitive score. Conclusion: Breast cancer patients had lower mean MMSE scores when compared to non-breast cancer controls. Hemoglobin level, breast cancer status, and educational level are significant predictors of the MMSE cognitive score. Clinicians should incorporate routine screening of cognitive functioning for breast cancer patients and further study is required to evaluate cognitive impairment among breast cancer patients in Ethiopia.

7132 POSTER Impairment of Cognitive Functioning During Sunitinib or Sorafenib Treatment – a Cross Sectional Study

2011 ◽  
Vol 47 ◽  
pp. S514 ◽  
Author(s):  
S.F. Mulder ◽  
D. Bertens ◽  
K.C.R. Vissers ◽  
C.J.A. Punt ◽  
P.F.A. Mulders ◽  
...  
Keyword(s):  
Cognitive Functioning ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Sorafenib Treatment

scholarly journals Out-of-Pocket Costs and Perceived Financial Burden Associated with Prostate Cancer Treatment in a Quebec Remote Area: A Cross-Sectional Study

2020 ◽  
Vol 28 (1) ◽  
pp. 26-39
Author(s):  
Abir El-Haouly ◽  
Anais Lacasse ◽  
Hares El-Rami ◽  
Frederic Liandier ◽  
Alice Dragomir
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Financial Burden ◽  
Cross Sectional Study ◽  
University Education ◽  
School Level ◽  
Sectional Study ◽  
Cross Sectional ◽  
Perceived Burden ◽  
Out Of Pocket Costs

Background: In publicly funded healthcare systems, patients do not pay for medical visits but can experience costs stemming from travel or over-the-counter drugs. We lack information about the extent of this burden in Canadian remote regions. This study aimed to: (1) describe prostate cancer-related out-of-pocket costs and perceived financial burden, and (2) identify factors associated with such a perceived burden among prostate cancer patients living in a remote region of the province of Quebec (Canada). Methods: A cross-sectional study was conducted among 171 prostate cancer patients who consulted at the outpatient clinic of the Centre Hospitalier de Rouyn-Noranda. Results: The majority of patients (83%) had incurred out-of-pocket costs for their cancer care. The mean total cost incurred in the last three months was $517 and 22.3% reported a moderate, considerable or unsustainable burden. Multivariable analysis revealed that having incurred higher cancer-related out-of-pocket costs (OR: 1.001; 95%CI: 1.001–1.002) private drug insurance (vs. public, OR: 5.23; 95%CI: 1.13–24.17) was associated with a greater perceived financial burden. Having better physical health-related quality of life (OR: 0.95; 95%CI: 0.913–0.997), a university education (vs. elementary/high school level, OR: 0.03; 95%CI: 0.00–0.79), and an income between $40,000 and $79,999 (vs. ≤ $39,999, OR: 0.15; 95%CI: 0.03–0.69) were associated with a lower perceived burden. Conclusion: Prostate cancer patients incur out-of-pocket costs even if they were diagnosed many years ago and the perceived burden is significant. Greater attention should be paid to the development of services to help patients manage this burden.

scholarly journals High neutrophil to lymphocytes ratio is associated with nutritional risk in hospitalised, unselected cancer patients: a cross-sectional study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jéssika M Siqueira ◽  
Jéssika D P Soares ◽  
Thaís C Borges ◽  
Tatyanne L N Gomes ◽  
Gustavo D Pimentel
Keyword(s):  
Logistic Regression ◽  
Cancer Patients ◽  
Systemic Inflammation ◽  
Roc Curve ◽  
Cross Sectional Study ◽  
Nutritional Risk ◽  
Sectional Study ◽  
Cross Sectional ◽  
Cut Point ◽  
Nrs 2002

AbstractCancer patients possess metabolic and pathophysiological changes and an inflammatory environment that leads to malnutrition. This study aimed to (i) determine whether there is an association between neutrophil-to-lymphocyte ratio (NLR) and nutritional risk, and (ii) identify the cut-off value of NLR that best predicts malnutrition by screening for nutritional risk (NRS 2002). This cross-sectional study included 119 patients with unselected cancer undergoing chemotherapy and/or surgery. The NRS 2002 was applied within 24 h of hospitalisation to determine the nutritional risk. Systemic inflammation was assessed by blood collection, and data on C-reactive protein (CRP), neutrophils, and lymphocytes were collected for later calculation of NLR. A receiver operating characteristic (ROC) curve was used to identify the best cut-point for NLR value that predicted nutritional risk. Differences between the groups were tested using the Student’s t-, Mann–Whitney U and Chi-Square tests. Logistic regression analyses were performed to assess the association between NLR and nutritional risk. The ROC curve showed the best cut-point for predicting nutritional risk was NLR > 5.0 (sensitivity, 60.9%; specificity, 76.4%). The NLR ≥ 5.0 group had a higher prevalence of nutritional risk than the NLR < 5.0 group (NLR ≥ 5.0: 73.6% vs. NLR < 5.0: 37.9%, p = 0.001). The NLR group ≥ 5.0 showed higher values of CRP and NLR than the NLR < 5.0 group. In addition, patients with NLR ≥ 5.0 also had higher NRS 2002 values when compared to the NLR < 5.0 group (NLR ≥ 5.0: 3.0 ± 1.1 vs. NLR < 5.0: 2.3 ± 1.2, p = 0.0004). Logistic regression revealed an association between NRS and NLR values. In hospitalised unselected cancer patients, systemic inflammation measured by NLR was associated with nutritional risk. Therefore, we highlight the importance of measuring the NLR in clinical practice, with the aim to detect nutritional risk.

Sign in / Sign up

Export Citation Format

Share Document